About

Biotech Briefings is a publication of Gibson Dunn’s Life Sciences Group — a forum to share insights, updates, and analysis on the latest developments across the life sciences industry. Our team of experienced attorneys, with deep knowledge in healthcare, biotechnology, pharmaceuticals, and medical devices, provides commentary on key regulatory changes, legal trends, and market innovations. The views expressed here are not the firm’s policies or a substitute for legal advice addressing specific facts and circumstances.

Gibson Dunn is committed to providing the highest quality legal services to our clients in a personal, responsive manner. The firm has more than 2,200 lawyers in offices located in major cities throughout the United States, Europe, South America, the Middle East, and Asia.

Our Life Sciences Group is consistently recognized as one of the leading practices in the United States. We deliver expertise and strategic guidance to companies across the biotechnology, pharmaceutical, diagnostics, and medical device industries — from global pharmaceutical leaders to emerging biotechnology companies — spanning capital markets, litigation, M&A, licensing and strategic transactions, regulatory compliance, and royalty-based financing.

For more information, please visit Gibson Dunn’s Life Sciences Group page.